BLRX BioLineRx Ltd: Bathi saben saham sajrone 12 wulan pungkasan

Aphexda sales dynamics and the development of the oncology portfolio influence the percentage growth history of EPS YoY (ttm), where 55.40 indicates the level of this metric for BioLineRx Ltd. (BLRX). Financial stability is based on the commercialization of approved drugs. Simultaneously, software robots are being implemented to accelerate data validation. This chart helps assess the stability of earnings per share, eliminating the risks of overpaying for the asset.

Bathi saben saham sajrone rolas wulan pungkasan BioLineRx Corp (BLRX): kanggo periode 11.02.2024 - 12.11.2026

BLRX (BioLineRx Corp): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:

Rega bursa biolinerx.com|BLRX - Bagan rega target

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar BioLineRx Ltd|BLRX - Nilai Perusahaan

- indikator kapitalisasi buku:

Nilai Akuntansi saben Saham BioLineRx|BLRX - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku biolinerx.com|BLRX - Aset Agregat Perusahaan

- indikator total utang lan likuiditas perusahaan:

- rincian bathi lan kelipatan pasar:

BLRX - Penghasilan resik|Bathi resik mangsa ngarep BioLineRx Ltd.|BLRX - Pangali P/E|Pangali mangsa ngarep rega marang bathi BioLineRx Ltd|BLRX - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan BioLineRx Ltd|BLRX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku BioLineRx|BLRX - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan biolinerx.com|BLRX - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep BioLineRx Ltd.

Pambiji fundamental perusahaan:BLRX biolinerx.com

This indicator measures the rolling annual growth rate of net earnings per share, smoothing out short-term fluctuations to identify the long-term profitability trend. By analyzing the rolling annual EPS YoY dynamics, an investor assesses the efficiency of BioLineRx Ltd. (BLRX) R&D expenditures in retaining leading oncologists through option programs and the capitalization of their scientific achievements.

Pesaing langsung